Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Rating Increased to Hold at StockNews.com

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM - Get Free Report) was upgraded by equities researchers at StockNews.com from a "sell" rating to a "hold" rating in a note issued to investors on Monday.

Other analysts have also issued research reports about the stock. Maxim Group raised their price target on shares of Actinium Pharmaceuticals from $20.00 to $30.00 and gave the company a "buy" rating in a research report on Tuesday, March 19th. HC Wainwright reissued a "buy" rating and issued a $50.00 price target on shares of Actinium Pharmaceuticals in a report on Monday. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $21.00 price objective on shares of Actinium Pharmaceuticals in a report on Monday, April 1st. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $25.72.

Actinium Pharmaceuticals Trading Up 8.2 %

Shares of Actinium Pharmaceuticals stock traded up $0.56 during trading on Monday, hitting $7.43. The stock had a trading volume of 244,842 shares, compared to its average volume of 322,240. Actinium Pharmaceuticals has a 12 month low of $4.00 and a 12 month high of $9.86. The firm has a market capitalization of $218.44 million, a PE ratio of -4.06 and a beta of 0.01.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM - Get Free Report) last posted its earnings results on Friday, March 29th. The biotechnology company reported ($0.33) EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.21. The business had revenue of $0.08 million for the quarter. As a group, sell-side analysts predict that Actinium Pharmaceuticals will post -1.87 earnings per share for the current fiscal year.

Institutional Trading of Actinium Pharmaceuticals

A number of large investors have recently made changes to their positions in ATNM. Brandywine Global Investment Management LLC acquired a new stake in Actinium Pharmaceuticals in the third quarter valued at $1,033,000. Sanders Morris Harris LLC purchased a new stake in shares of Actinium Pharmaceuticals in the first quarter valued at $78,000. Finally, Creative Financial Designs Inc. ADV grew its holdings in Actinium Pharmaceuticals by 19.1% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company's stock valued at $101,000 after buying an additional 3,175 shares during the period. 27.50% of the stock is owned by institutional investors and hedge funds.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.